scholarly journals Role of parathyroid hormone therapy in reversing radiation-induced nonunion and normalization of radiomorphometrics in a murine mandibular model of distraction osteogenesis

Head & Neck ◽  
2013 ◽  
Vol 35 (12) ◽  
pp. 1732-1737 ◽  
Author(s):  
K. Kelly Gallagher ◽  
Sagar Deshpande ◽  
Catherine N. Tchanque-Fossuo ◽  
Alexis Donneys ◽  
Deniz Sarhaddi ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Hormone Therapy ◽  
Distraction Osteogenesis ◽  
Radiation Induced

scholarly journals Parathyroid Hormone Therapy Mollifies Radiation-Induced Biomechanical Degradation in Murine Distraction Osteogenesis

2013 ◽  
Vol 132 (1) ◽  
pp. 91e-100e ◽  
Author(s):  
Sagar S. Deshpande ◽  
Katherine K. Gallagher ◽  
Alexis Donneys ◽  
Catherine N. Tchanque-Fossuo ◽  
Deniz Sarhaddi ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Hormone Therapy ◽  
Distraction Osteogenesis ◽  
Radiation Induced

scholarly journals Parathyroid hormone reverses radiation induced hypovascularity in a murine model of distraction osteogenesis

Bone ◽  
2013 ◽  
Vol 56 (1) ◽  
pp. 9-15 ◽  
Author(s):  
Stephen Y. Kang ◽  
Sagar S. Deshpande ◽  
Alexis Donneys ◽  
Jose J. Rodriguez ◽  
Noah S. Nelson ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Distraction Osteogenesis ◽  
Murine Model ◽  
Radiation Induced

Stem cell and intermittent parathyroid hormone therapy creates superior regenerate in murine mandibular distraction osteogenesis following radiation

2012 ◽  
Vol 215 (3) ◽  
pp. S81
Author(s):  
Sagar Satish Deshpande ◽  
Steven R. Buchman ◽  
Alexis Donneys ◽  
Kelly K. Gallagher ◽  
Catherine N. Tchanque-Fossuo ◽  
...  
Keyword(s):  
Stem Cell ◽  
Parathyroid Hormone ◽  
Hormone Therapy ◽  
Distraction Osteogenesis ◽  
Mandibular Distraction ◽  
Mandibular Distraction Osteogenesis

scholarly journals Role of parathyroid hormone in regeneration of irradiated bone in a murine model of mandibular distraction osteogenesis

Head & Neck ◽  
2016 ◽  
Vol 39 (3) ◽  
pp. 464-470 ◽  
Author(s):  
Stephen Y. Kang ◽  
Sagar S. Deshpande ◽  
Alexander R. Zheutlin ◽  
Alexis Donneys ◽  
Jose J. Rodriguez ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Distraction Osteogenesis ◽  
Murine Model ◽  
Mandibular Distraction ◽  
Mandibular Distraction Osteogenesis

The role of orexin A in pathophysiological mechanisms of sleep disorder in postmenopausal women

GYNECOLOGY ◽  
2020 ◽  
Vol 22 (1) ◽  
pp. 50-54
Author(s):  
Zukhra Kh. Ebzieva ◽  
Svetlana V. Yureneva ◽  
Tatiana Yu. Ivanets
Keyword(s):  
Hormone Therapy ◽  
Sleep Disorder ◽  
Postmenopausal Women ◽  
Menopausal Hormone Therapy ◽  
Reproductive Age ◽  
Vasomotor Symptoms ◽  
Women Of Reproductive Age ◽  
Orexin A ◽  
Group 1

Aim. To conduct a comparative analysis of serum orexin A levels in women of different age periods with and without sleep disorder and vasomotor symptoms. To evaluate the dynamics of orexin A levels under menopausal hormone therapy. Materials and methods. The study included 50 postmenopausal women and 30 women of reproductive age with a regular menstrual cycle. Using block randomization, patients are divided into 3 groups: group 1 (main group), n=25, -STRAW+ 10 (+1b and +1c), patients with sleep disorder and vasomotor symptoms; group 2 (comparison group), n=25, STRAW+ 10 (+1b and +1c), patients with vasomotor symptoms without sleep disorder; group 3 (control group), n=30, STRAW+ 10 (-4), women of reproductive age without sleep disorder. Group 1 patients were given menopausal hormone therapy. A comparative analysis was carried out using the questionnaire for assessing menopausal symptoms severity by the Greene Scale (the Greene Climacteric Scale) and Rating Scale for subjective sleep characteristics. After 12 weeks of treatment, a control examination was performed. Results. In group 1 women, the serum orexin A levels were significantly higher compared to the women without the symptoms. The link between the orexin A levels and menopause syndrome severity was established. A significant decrease in the menopausal symptoms severity after 12 weeks of menopausal hormone therapy was shown. It was accompanied by a 1,3-fold decrease in orexin A levels. Conclusions. The obtained data indicate the possible role of orexin A and the orexin neuropeptide system in the pathogenesis of sleep disorder and vasomotor symptoms in postmenopausal women.

The role of the clinical pharmacist in guiding adjuvant hormonal therapy in patients with breast cancer

2021 ◽  
pp. 107815522110293
Author(s):  
Amanda V Pirolli ◽  
Tatiana Brusamarello ◽  
Stella S Everton ◽  
Vânia M S Andrzejevski
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Hormonal Therapy ◽  
Clinical Pharmacist ◽  
Tertiary Care ◽  
Structured Interview ◽  
Care Hospital ◽  
Adjuvant Hormonal Therapy ◽  
Breast Cancers

Breast cancer is the most prevalent type of cancer among women, affecting about 2.1 million worldwide and is responsible for the highest number of cancer-related deaths among women. Approximately 80% of breast cancers express on the surface of hormone receptor cells, such as progesterone and estrogen. In these cases, Adjuvant Hormonal Therapy (AHT) is indicated for a period of five to ten years and consists of taking a daily oral pill. The two most used drugs in AHT are tamoxifen and Aromatase Inhibitors. One of the issues most faced by individuals who are subjected to long periods of treatment is the lack of medication adherence and, consequently, therapeutic inefficiency. It is believed that the monitoring by the pharmacist can contribute to the reduction of errors inherent to the medication, making the treatment more effective and improving the patient's quality of life. The present study aimed to know the perception of patients who live with breast cancer and who do AHT in relation to the educational performance of the clinical pharmacist. This is a qualitative, descriptive and exploratory study, carried out from March to October 2020, with 15 women undergoing treatment at the oncology unit of a tertiary-care hospital in south of Brazil. The data were obtained through a semi-structured interview using an instrument composed of two parts, one referring to the characterization of the participants and the other with the guiding question of the research: "How do you perceive the role of the pharmacist in relation to the guidelines for the use of adjuvant hormonal therapy?". The method of theoretical saturation was used to perform the sample closure and the thematic analysis was used to analyze the data. The participants were between 32 and 74 years old, seven were on tamoxifen therapy and eight on anastrozole, ten were on the first year of treatment, two on the second and three on the third year. The themes that emerged were: pharmacist-patient interaction as a safety factor in hormone therapy; role of the pharmacist in the development of strategies for self-management of the patients during hormone therapy; and, challenges for the pharmacist in relation to hormone therapy through continued guidance. It was evident that the pharmacist's educational action encouraged the participants to carry out the treatment in a more confident and assertive manner according to their particularities and beliefs.

Sign in / Sign up

Export Citation Format

Share Document